Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies

Perampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an adjunctive treatment for FIRES (febrile infection-related epilepsy syndrome) and other drug-resistant epilepsies. A single-cent...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guo Yong Lim BSc(Pharm.)(Hons.), Chun Liang Chen PharmD, BCPPS, Derrick Chan Wei Shih MCI
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Pediatrics RJ1-570 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/fbd11a58dee249bcbf5074a81317f09a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fbd11a58dee249bcbf5074a81317f09a
record_format	dspace
spelling	oai:doaj.org-article:fbd11a58dee249bcbf5074a81317f09a2021-11-21T01:03:46ZUtility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies2329-048X10.1177/2329048X211055335https://doaj.org/article/fbd11a58dee249bcbf5074a81317f09a2021-11-01T00:00:00Zhttps://doi.org/10.1177/2329048X211055335https://doaj.org/toc/2329-048XPerampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an adjunctive treatment for FIRES (febrile infection-related epilepsy syndrome) and other drug-resistant epilepsies. A single-centre, observational, retrospective study involving 20 pediatric patients was conducted. Perampanel was started for three patients with FIRES, achieving seizure cessation in two patients within a day and on days 19 and 32 of illness. Doses used ranged from 4 to 12 mg/day, without any adverse effects reported or discontinuation of therapy. Responder-rate for other drug-resistant epilepsies is 25%. Median time to achieve ≥50% seizure reduction was 80 days (range: 26-326 days). Adverse effect reported in 47% of the patients includes central nervous system-related, and thrombocytopenia. Eight patients discontinued perampanel, because of ineffectiveness or adverse effects. The median time on perampanel before discontinuation was 179 days (range: 94-345 days). Perampanel may be of benefit in pediatrics FIRES and is of utility in other drug-resistant epilepsies.Guo Yong Lim BSc(Pharm.)(Hons.)Chun Liang Chen PharmD, BCPPSDerrick Chan Wei Shih MCISAGE PublishingarticlePediatricsRJ1-570Neurology. Diseases of the nervous systemRC346-429ENChild Neurology Open, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pediatrics RJ1-570 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Pediatrics RJ1-570 Neurology. Diseases of the nervous system RC346-429 Guo Yong Lim BSc(Pharm.)(Hons.) Chun Liang Chen PharmD, BCPPS Derrick Chan Wei Shih MCI Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
description	Perampanel is a novel antiepileptic drug, which antagonises AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. We describe perampanel as an adjunctive treatment for FIRES (febrile infection-related epilepsy syndrome) and other drug-resistant epilepsies. A single-centre, observational, retrospective study involving 20 pediatric patients was conducted. Perampanel was started for three patients with FIRES, achieving seizure cessation in two patients within a day and on days 19 and 32 of illness. Doses used ranged from 4 to 12 mg/day, without any adverse effects reported or discontinuation of therapy. Responder-rate for other drug-resistant epilepsies is 25%. Median time to achieve ≥50% seizure reduction was 80 days (range: 26-326 days). Adverse effect reported in 47% of the patients includes central nervous system-related, and thrombocytopenia. Eight patients discontinued perampanel, because of ineffectiveness or adverse effects. The median time on perampanel before discontinuation was 179 days (range: 94-345 days). Perampanel may be of benefit in pediatrics FIRES and is of utility in other drug-resistant epilepsies.
format	article
author	Guo Yong Lim BSc(Pharm.)(Hons.) Chun Liang Chen PharmD, BCPPS Derrick Chan Wei Shih MCI
author_facet	Guo Yong Lim BSc(Pharm.)(Hons.) Chun Liang Chen PharmD, BCPPS Derrick Chan Wei Shih MCI
author_sort	Guo Yong Lim BSc(Pharm.)(Hons.)
title	Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
title_short	Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
title_full	Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
title_fullStr	Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
title_full_unstemmed	Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies
title_sort	utility and safety of perampanel in pediatric fires and other drug-resistant epilepsies
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/fbd11a58dee249bcbf5074a81317f09a
work_keys_str_mv	AT guoyonglimbscpharmhons utilityandsafetyofperampanelinpediatricfiresandotherdrugresistantepilepsies AT chunliangchenpharmdbcpps utilityandsafetyofperampanelinpediatricfiresandotherdrugresistantepilepsies AT derrickchanweishihmci utilityandsafetyofperampanelinpediatricfiresandotherdrugresistantepilepsies
_version_	1718419401119629312

Utility and Safety of Perampanel in Pediatric FIRES and Other Drug-Resistant Epilepsies

Ejemplares similares